Want to see SE:BINV full AI Analyst Report?
BINV Stock Chart & Stats
kr30.30
kr0.20(0.78%)
At close: 4:00 PM EST
kr30.30
kr0.20(0.78%)
Day’s Range― - ―
52-Week Rangekr19.22 - kr41.60
Previous CloseN/A
Volume47.26K
Average Volume (3M)91.72K
Market Cap
kr1.68B
Enterprise Valuekr1.20B
Total Cash (Recent Filing)kr456.48M
Total Debt (Recent Filing)kr6.25M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Aug 27, 2026EPS Estimate
-1.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.09
Shares Outstanding65,804,360
10 Day Avg. Volume84,851
30 Day Avg. Volume91,723
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.47
Price to Sales (P/S)8.54
P/FCF Ratio-7.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr90.00Price Target Upside197.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-8.13
Revenue Forecast (FY)kr208.10M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Financial FlexibilityVery low debt (≈2% of equity) is a durable structural strength: it reduces refinancing and interest-rate risk and preserves capacity to raise capital or absorb development setbacks. This flexibility supports multi-quarter R&D investment and partnership activity without heavy fixed-charge constraints.
Proprietary Discovery PlatformsOwning proprietary antibody discovery and validation platforms is a long-lived competitive asset. It enables repeatable candidate generation, increases partner leverage in deals, and underpins recurring collaboration/licensing revenue potential, supporting sustainable pipeline replenishment and partner interest.
High Gross Margins On RevenueNear-100% gross profit implies the company's revenue streams (licenses, milestones, royalties) are highly scalable and not tied to heavy COGS. Structurally, this means additional revenue from partnerships or future sales could flow to operating profit more directly, enhancing operational leverage as top line grows.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow of roughly -260M TTM is a structural weakness: it forces repeated external funding, increases dilution risk, and constrains the firm's ability to advance multiple programs simultaneously. Over months this limits strategic optionality and increases financing dependence.
Deep Operating LossesOperating and net losses materially exceed revenue (~1.5x TTM), indicating the cost base is structurally misaligned with current income. This persistent unprofitability depresses returns on equity, necessitates frequent capital raises or partner dealmaking, and lengthens the timeline to self-sustaining operations.
Revenue Volatility And Recent DeclineRevenue is lumpy and fell -3.8% TTM after prior gains, reflecting milestone-driven and partnership timing. This structural volatility makes cash flow forecasting and steady investment planning difficult, increasing execution risk for clinical programs and reliance on the timing of external partner payments.
BioInvent International AB News
BINV FAQ
What was BioInvent International AB’s price range in the past 12 months?
BioInvent International AB lowest stock price was kr19.22 and its highest was kr41.60 in the past 12 months.
What is BioInvent International AB’s market cap?
BioInvent International AB’s market cap is kr1.68B.
When is BioInvent International AB’s upcoming earnings report date?
BioInvent International AB’s upcoming earnings report date is Aug 27, 2026 which is in 52 days.
How were BioInvent International AB’s earnings last quarter?
BioInvent International AB released its earnings results on Apr 29, 2026. The company reported -kr1.903 earnings per share for the quarter, the consensus estimate of -kr1.903 by kr0.
Is BioInvent International AB overvalued?
According to Wall Street analysts BioInvent International AB’s price is currently Undervalued.
Does BioInvent International AB pay dividends?
BioInvent International AB does not currently pay dividends.
What is BioInvent International AB’s EPS estimate?
BioInvent International AB’s EPS estimate is -1.9.
How many shares outstanding does BioInvent International AB have?
BioInvent International AB has 65,804,360 shares outstanding.
What happened to BioInvent International AB’s price movement after its last earnings report?
BioInvent International AB reported an EPS of -kr1.903 in its last earnings report, expectations of -kr1.903. Following the earnings report the stock price went up 3.944%.
Which hedge fund is a major shareholder of BioInvent International AB?
Currently, no hedge funds are holding shares in SE:BINV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioInvent International AB
BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and Japan. Its most advanced therapeutic candidate, BI-1206, targets non-Hodgkin lymphoma and various solid tumors. The company's diverse pipeline also features developments aimed at tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system, alongside BT-001 for solid tumors. Furthermore, BioInvent is progressing BI-1808 and BI-1910, a pair of anti-TNFR2 antibodies, designed to combat solid tumors and cutaneous T-cell lymphoma. Strategic collaborations are integral to its operations; these include a partnership with Pfizer Inc. for antibody development against tumor-associated myeloid cells, a co-development effort with Transgene involving multi-functional oncolytic viruses for solid tumors, and an agreement with Merck for the clinical advancement and supply of BI-1808. Established in 1996, BioInvent is based in Lund, Sweden.
BINV Company Deck
BINV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents multiple strong clinical data points (notably BI-1808 in ovarian cancer and CTCL, and BI-1206 in NHL) with supportive safety and clear near-term catalysts and collaborations with Merck and AstraZeneca. Financially, Q4 sales fell sharply due to lower contract production while full-year sales increased materially driven by one-time items; operating costs and losses rose and the company states it is financed for only the next 12 months, meaning further financing or partnering will be needed to sustain a larger pivotal development plan. Overall, the positive clinical momentum and strategic partnerships outweigh short-term financial and execution risks, but upcoming readouts will be critical for de-risking future funding and pivotal starts.View all SE:BINV earnings summariesBINV Stock 12 Month Forecast
Average Price Target
kr90.00
▲(197.03% Upside)
Technical Analysis
Hansa Biopharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---